CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-12-10): Pfizer pulls Thelin (sitaxsentan sodium) off market due to liver injury

Industry

Pfizer pulls Thelin (sitaxsentan sodium) off market due to liver injury

Last Updated: 2010-12-10 11:20:04 -0400 (Reuters Health)

BOSTON (Reuters) - Pfizer Inc said on Friday it is halting clinical trials of Thelin (sitaxsentan sodium) to treat pulmonary arterial hypertension and withdrawing it from markets where it has been approved, after it was found to be associated with potentially life-threatening liver toxicity.

Pfizer said it has concluded that the risks of the drug outweigh the overall benefit for patients with PAH.

Thelin generated sales of $44.4 million in the first nine months of 2010.

The company is withdrawing the drug from regions in which it is already approved - the European Union, Canada and Australia. Thelin competes with Tracleer (bosentan), a drug made by Actelion Ltd. and with Letairis (ambrisentan), a drug made by Gilead Sciences.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.